Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a twice-yearly injectable.

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection. The recommendation, issued at the International AIDS Conference in Kigali,

After the virologic failure of cabotegravir/rilpivirine and despite dual-class resistance mutations, Canadian doctors have had surprising success with a single pill of the integrase inhibitor bictegravir.

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for groups most at risk and in areas where the burden of HIV remains high.

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting injectable HIV treatment cabotegravir.

Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts said at the International AIDS Society conference on HIV science in Rwanda on Monday.

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting to a years-long kickback scheme to promote its panel of HIV medications. The California-based drug company reached a $202 million settlement with a coalition of 49 states led by New York for incentivizing doctors to prescribe its HIV meds with hundreds of thousands of dollars in payments,

Newborns exposed to HIV during pregnancy or birth should receive preventive antiretroviral medication immediately after delivery to reduce the risk of transmission from mother to child.

Freda Jones, founder of LOTUS, empowers women living with HIV in Atlanta through a peer-led support group. Peer support is crucial for HIV care.

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir. Research shows the shot could help end Aids in the country.